1What 211.188 requires.
Section 211.188 sits in Subpart J, Records and Reports, of 21 CFR Part 211, FDA’s regulation setting the minimum current good manufacturing practice for preparing drug products for people or animals.¹ It requires batch production and control records “for each batch of drug product produced”, including “complete information relating to the production and control of each batch”.²
The record has two parts. Paragraph (a) asks for “an accurate reproduction of the appropriate master production or control record, checked for accuracy, dated, and signed”, so each batch starts from the approved instructions in its master record under 211.186.²³ Paragraph (b) asks for documentation “that each significant step in the manufacture, processing, packing, or holding of the batch was accomplished”, and lists thirteen things that documentation includes.²
2The thirteen items, and the sections behind them.
Other sections of Part 211 say what must be checked for several of the items, by whom, and in some cases that the result goes into the batch record.¹
| 211.188(b) | What to record | Related requirement |
|---|---|---|
| (1) | Dates | Time limits for each phase where they are set, with any deviation justified and documented (211.111) |
| (2) | Identity of individual major equipment and lines used | Each major item’s distinctive number or code recorded in the batch record (211.105(b)); for dedicated equipment, cleaning, maintenance and use records form part of the batch record (211.182) |
| (3) | Specific identification of each batch of component or in-process material used | Dispensed containers labelled with the component, its receiving number, the weight and the batch it is for (211.101(b)) |
| (4) | Weights and measures of components used | Each dispensed container examined by a second person and each addition verified, or one person verifying automated equipment (211.101(c) and (d)) |
| (5) | In-process and laboratory control results | In-process controls and tests under written procedures (211.110) |
| (6) | Inspection of the packaging and labelling area before and after use | Results of the line inspection documented in the batch record (211.130(e)) |
| (7) | Actual yield and percentage of theoretical yield at appropriate phases | Calculated and independently verified (211.103), against the limits in the master record (211.186(b)(7)) |
| (8) | Complete labelling control records, with specimens or copies of all labelling used | Examination of labelling issued, and reconciliation of labelling issued, used and returned (211.125, 211.130(d)) |
| (9) | Description of drug product containers and closures | As described in the master record (211.186(b)(8)) |
| (10) | Any sampling performed | Sampling and testing under written procedures (211.110, 211.165(c)) |
| (11) | People performing and directly supervising or checking each significant step, or the person checking a step done by automated equipment | Automated equipment used in conformity with 211.68 |
| (12) | Any investigation made under 211.192 | Unexplained discrepancies and specification failures investigated, with a written record (211.192) |
| (13) | Results of examinations made under 211.134 | Packaged and labelled product examined for correct labelling, with results recorded (211.134(c)) |
The automation wording in item (11), and in 211.68(c), 211.101, 211.103 and 211.182, dates from a September 2008 amendment: automated equipment can take the place of a second person, provided one person checks that the equipment performed the operation properly. FDA described the change as consistent with its “longstanding interpretation”, and it took effect on 8 December 2008.¹⁴
3What “complete information” means.
FDA’s 2018 data integrity guidance lists 211.188 among the sections requiring “complete information”, and expects data to be kept with “all associated metadata required to reconstruct the CGMP activity”.⁵ It draws several practical consequences.
- Actions must be attributable to a specific individual. Shared logins do not meet the requirements, 211.188(b)(11) among them, for actions such as a second-person check to be attributable.⁵
- Production steps are documented at the time of performance, as 211.100(b) requires.¹ FDA does not accept data recorded on pieces of paper that are discarded after transcription.⁵
- A result invalidated after a scientifically sound investigation stays in the batch record given to the quality unit, with the investigation report that justifies invalidating it.⁵
- An electronic batch record system can be designed to save after each entry, which FDA likens to “indelibly recording each entry contemporaneously on a paper batch record”.⁵
4How the EU and ICH Q7 lists compare.
EU GMP Chapter 4 lists the contents of the Batch Processing Record in 4.20 and the Batch Packaging Record in 4.21, and ICH Q7 lists the contents of API batch production records in 6.52.⁶⁷
| Element | 21 CFR 211.188 | EU GMP Chapter 4.20 and 4.21 | ICH Q7 6.52 |
|---|---|---|---|
| Timing | Dates | Dates and times of start, significant intermediate stages and completion | Dates and, when appropriate, times |
| Process values | Each significant step, with weights and measures | Any relevant processing operation or event, and major equipment | Actual results recorded for critical process parameters |
| People | People performing and directly supervising or checking | Initials of the operators and, where appropriate, the name of the checker | Signatures of people performing and directly supervising or checking each critical step |
| Deviations | Any investigation under 211.192 | Notes on special problems, with signed authorisation for any deviation | Any deviation, its evaluation and investigation, or a reference to it |
| Testing | In-process and laboratory control results | In-process control results, with the initials of who carried them out | In-process and laboratory test results, and results of release testing |
| Packaging | In the same record | A separate Batch Packaging Record, with reconciliation of printed packaging materials | Description of packaging and label |
| Approval | Quality unit review under 211.192 | Approval by the person responsible for the operation | Quality unit review under 6.7 |
Chapter 4 adds that where a validated process is continuously monitored and controlled, automatically generated reports may be limited to compliance summaries and exception and out-
5Keeping and reviewing the record.
Batch records are kept for at least one year after the batch’s expiration date, or three years after distribution for certain OTC products exempt from expiration dating. They are readily available for inspection where the work happened; records that can be retrieved immediately by computer from another location meet that requirement, and true copies are acceptable.¹ Before the batch is released, the quality control unit reviews and approves the complete record under 211.192.¹
6How it runs in Seal.
In Seal’s electronic batch records, the approved master becomes an executable workflow and the batch record keeps the version it ran on. Scanned containers are checked for identity, status, expiry and quantity before a step proceeds, equipment qualification, calibration and cleaning status and the user’s training are checked before a step begins, and performance, verification, review and approval signatures each carry the signer, time and meaning. In weigh and dispense, the container scan, the gross, tare and net readings and the verification are recorded against the batch step, with the original values retained.
For material accountability, the batch material reconciliation guide reconciles the quantity issued with evidenced consumption, returns, samples and waste on the same quantity basis, and keeps any unexplained difference open until evidence explains it.
References
- 121 CFR Part 211, Current good manufacturing practice for finished pharmaceuticals, sections 211.1, 211.68, 211.100 to 211.134, 211.165, 211.180, 211.182 and 211.192, eCFR, current to 4 November 2026. https:/
/ www. ecfr. gov/ current/ title- 21/ chapter- I/ subchapter- C/ part- 211 (read 6 November 2026) - 221 CFR 211.188, Batch production and control records, eCFR, current to 4 November 2026. https:/
/ www. ecfr. gov/ current/ title- 21/ chapter- I/ subchapter- C/ part- 211/ subpart- J/ section- 211. 188 (read 6 November 2026) - 321 CFR 211.186, Master production and control records, eCFR, current to 4 November 2026. https:/
/ www. ecfr. gov/ current/ title- 21/ chapter- I/ subchapter- C/ part- 211/ subpart- J/ section- 211. 186 (read 6 November 2026) - 4Amendments to the Current Good Manufacturing Practice Regulations for Finished Pharmaceuticals, final rule, 73 FR 51919, FDA, 8 September 2008. https:/
/ www. federalregister. gov/ documents/ 2008/ 09/ 08/ E8- 20709/ amendments- to- the- current- good- manufacturing- practice- regulations- for- finished- pharmaceuticals (read 6 November 2026) - 5Data Integrity and Compliance With Drug CGMP: Questions and Answers, guidance for industry, sections II and III, FDA, December 2018. https:/
/ www. fda. gov/ media/ 119267/ download (read 6 November 2026) - 6EudraLex Volume 4, Part I, Chapter 4: Documentation, sections 4.20 and 4.21, European Commission, in operation since 30 June 2011. https:/
/ health. ec. europa. eu/ system/ files/ 2016- 11/ chapter4_ 01- 2011_ en_ 0. pdf (read 6 November 2026) - 7ICH Q7, Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients, section 6.5, ICH, Step 4, 10 November 2000. https:/
/ database. ich. org/ sites/ default/ files/ Q7%20Guideline. pdf (read 6 November 2026)
AQuestions and answers
Does 21 CFR 211.188 apply to active pharmaceutical ingredients?
Part 211 sets CGMP for finished pharmaceuticals. For active pharmaceutical ingredients, FDA points to ICH Q7, which it publishes as guidance for industry; section 6.5 of Q7 sets out what API batch production records should contain.
Does 211.188 require times as well as dates?
Section 211.188(b)(1) asks for dates. Times come in where another requirement needs them, for example time limits for production phases under 211.111, and equipment logs under 211.182 show the date and time of each batch. EU GMP Chapter 4 asks for dates and times of the start, significant intermediate stages and completion of production.
Does every batch record need a copy of the master record?
Yes. Paragraph (a) of 211.188 requires an accurate reproduction of the appropriate master production or control record, checked for accuracy, dated and signed. In an electronic system, FDA expects the workflow that creates the electronic master record to be validated, so that its steps, requirements and calculations are correct.
Who has to be identified at each step?
Section 211.188(b)(11) asks the record to identify the people performing and directly supervising or checking each significant step. Where automated equipment performs the step under 211.68, only the person checking the equipment’s work needs to be identified. The section asks for identification rather than a signature; for APIs, ICH Q7 asks for the signatures of the people performing and checking each critical step.
Can a batch production record be kept electronically?
Yes. Part 11 sets the controls for electronic records and signatures, and FDA accepts electronic signatures with appropriate controls in any CGMP record. The workflow that creates the record has to be validated for its intended use, including its calculations.